About us Contacts Drug interactions: 390 212
Drug search by name

Complera and Pradaxa

Determining the interaction of Complera and Pradaxa and the possibility of their joint administration.

Check result:
Complera <> Pradaxa
Relevance: 14.08.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Rilpivirine may increase the blood levels and effects of dabigatran. Combining these medications may increase the risk of anemia and bleeding complications. Let your doctor know if you have kidney disease, as you may need a dose adjustment of dabigatran, or you may not be able to take the medication at all. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: The coadministration of rilpivirine with dabigatran may theoretically increase the bioavailability of dabigatran. In vitro, rilpivirine has been shown to be an inhibitor of P-glycoprotein (P-gp). Dabigatran etexilate is a substrate of P-gp. Rilpivirine did not affect the pharmacokinetics of digoxin, another P-gp substrate, in a clinical study. However, concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.

MANAGEMENT: Pharmacologic response to dabigatran should be monitored more closely whenever rilpivirine is added to or withdrawn from therapy, and the dabigatran dosage adjusted as necessary. Patients should be monitored for the development of anemia and bleeding complications during coadministration.

References
  • "Product Information. Complera (emtricitabine/rilpivirine/tenofovir)." Gilead Sciences, Foster City, CA.
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Complera

Generic Name: emtricitabine / rilpivirine / tenofovir

Brand name: Complera, Odefsey

Synonyms: n.a.

Pradaxa

Generic Name: dabigatran

Brand name: Pradaxa

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction